From IV to Oral: Leveraging Softgel to Extend Vinorelbine’s Lifecycle & Improve Patient Convenience
³§³Ü³¾³¾²¹°ù²â:​â¶Ä‹ Vinorelbine, a chemotherapy agent traditionally given by IV infusion, was reformulated into the first approved oral softgel capsule through a collaboration between Pierre Fabre and ̽»¨ºÏ¼¯. This innovation improved patient convenience, enabled treatment at home, and sustained brand value despite the entry of intravenous generics. Using ̽»¨ºÏ¼¯â€™s softgel technology and dedicated cytotoxic manufacturing expertise, the new oral vinorelbine achieved bioequivalent systemic exposure to the IV product, offering oncologists and patients a flexible oral/IV switch strategy. This case study highlights how oral oncology drug development with softgel can extend product lifecycles while enhancing patient outcomes.